New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

LONG BEACH, Calif. -- Outcomes in neovascular age-related macular degeneration (nAMD) failed to improve with the addition of ...

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

Investigators defined an IOP spike as >40 mm Hg or an increase ≥10 mm Hg after injection. The population was older (mean age ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

Biosimilars for aflibercept 2 mg make sense because aflibercept is used globally by a majority of clinicians, and they will provide “a lot of help to our patients,” he said.

D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that ...